...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of neurology >Long-lasting benefits of botulinum toxin type B in Parkinson's disease-related drooling.
【24h】

Long-lasting benefits of botulinum toxin type B in Parkinson's disease-related drooling.

机译：B型肉毒杆菌毒素在帕金森氏病相关的流口水中具有持久的益处。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

PURPOSE: To investigate the safety, efficacy and effectiveness of botulinum toxin type-B (BTX-B) injections into the parotid glands to reduce drooling in Parkinson's disease (PD) subjects. METHODS: A double-blind, randomised, placebo-controlled study enrolled 36 advanced phase PD subjects who complained of disabling drooling. Patients received either 4000U BTX-B or placebo. Anatomically guided injections were performed. Outcome measures were chosen to assess both the subjective feeling of improvement (i. e. the Drooling Severity and Frequency Scale, DSFS, visuo-analogic ratings of familial distress, VAS-FD, and social distress, VAS-SD) and objective saliva reduction (saliva production over five minutes was checked by weighing dental rolls). The Global Impression Score (GIS) was also applied, rating improvement from 0 to 3. RESULTS: One month after injections, BTX-B patients showed a meaningful improvement in almost all subjective outcomes. Two-way analysis of variance gave a significant time x treatment effect, F-value being 52.5 (p < 0.0001) for DS-FS, 23.2 (p < 0.0001) for VAS-FD, 29 (p < 0.0001) for VAS-SD, and 28.9 (p < 0.0001) for UPDRSADL drooling item score. All BTX-B subjects declared sialorrhea reduction of any kind (moderate for 44.4% cases, and dramatic for 33.3% subjects), at variance with 61.1% controls who denied any benefit from treatment. (Chi-square = 22.9; p < 0.0001). When present, benefits lasted on average 19.2 +/- 6.3 weeks in the BTX-B group compared to 6.7 +/- 1.4 weeks in controls (T-value: 26.4; p < 0.0001). CONCLUSIONS: BTXB represents a safe and efficacious tool for the management of PD-related drooling, ensuring a longlasting waning of this disabling symptom.
机译：目的：研究腮腺中注射B型肉毒毒素（BTX-B）的安全性，有效性和有效性，以减少帕金森氏病（PD）受试者的流口水。方法：一项双盲，随机，安慰剂对照研究纳入了36名抱怨禁用流口水的晚期PD受试者。患者接受4000U BTX-B或安慰剂治疗。进行了解剖学指导的注射。选择结果测量来评估主观的改善感（即流口水的严重程度和频率量表，DSFS，家族性窘迫的视觉模拟评分，VAS-FD和社会窘迫，VAS-SD）和客观唾液减少（唾液产生）在五分钟内通过称量牙辊来检查）。还应用了全球印象得分（GIS），等级从0提升到3。结果：注射后一个月，BTX-B患者几乎在所有主观结局中均表现出有意义的改善。双向方差分析给出了显着的时间x处理效果，DS-FS的F值为52.5（p <0.0001），VAS-FD的F值为23.2（p <0.0001），VAS-SD的F值为29（p <0.0001） ，UPDRSADL流口水项得分为28.9（p <0.0001）。所有BTX-B受试者均宣布任何形式的唾液减少（44.4％的病例为中度，33.3％的受试者为戏剧性），与拒绝接受任何治疗益处的61.1％对照者差异较大。 （卡方= 22.9; p <0.0001）。如果存在的话，BTX-B组的获益平均持续19.2 +/- 6.3周，而对照组为6.7 +/- 1.4周（T值：26.4; p <0.0001）。结论：BTXB代表一种安全有效的工具，可用于治疗PD相关的流口水，确保这种致残症状的持久消失。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号